Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 12, 2017

M&As this week: Allergan, Roche Holdings, Pharmaron

Irish pharmaceutical company Allergan has entered an option agreement with the shareholders of US-based Lysosomal Therapeutics (LTI), giving the former the right to acquire the latter.

Irish pharmaceutical company Allergan has entered an option agreement with the shareholders of US-based Lysosomal Therapeutics (LTI), giving the former the right to acquire the latter.

LTI is engaged in small-molecule research and development targeting neurodegeneration diseases.

The acquisition will take place upon completion of a Phase I b trial for LTI-291, LTI’s lead programme that targets Parkinson’s Disease.

Allergan will make an upfront research and development payment for the drug candidate, as part of the agreement and the two companies will form a joint committee that will oversee LTI-291’s development.

Allergan expects to enter the Parkinson’s Disease market through the acquisition.

"US-based contract research company Pharmaron has completed the acquisition of biotechnology company Xceleron."

US-based biotechnology company ForSight VISION4 has been acquired by Roche Holdings for an upfront payment in addition to earn-out payments based on the achievement of certain development and commercial milestones.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Roche will gain access to the target company’s PDS technology, which is used for long-acting delivery of therapeutics to the eye.

Roche has acquired the company from US-based medical device organisation ForSight Labs.

US-based contract research company Pharmaron has completed the acquisition of biotechnology company Xceleron.

Through the acquisition, Pharmaron aims to differentiate and strengthen its offerings in translational science and clinical development services, as well as research and development (R&D) collaborations worldwide.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU